Shareholder Votes

INCYTE CORP shareholders approved Election of Directors at the 2026-06-08 meeting.

“The following directors were elected: For Against Abstain Broker Non-Votes Julian C. Baker 140,340,036 33,157,541 723,111 11,426,181”

Arcutis Biotherapeutics, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2026-06-05 meeting.

“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”

Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.

“Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026”

Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected at the 2026-06-05 meeting.

“Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected”

Offerpad Solutions Inc. shareholders approved Approval of amendments to Certificate of Incorporation to effect a reverse stock split of Common Stock at ratio range of 1-for-5 to 1-for-50, subject to Board discretion to abandon at the 2026-06-03 meeting.

“Proposal 4 - Approval of amendments to the Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-5 and 1-for-50, as determined by the Company’s Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon such amendments (the “Reverse Stock Split Amendment”). Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 19,191,573 3,299,278 5,138,097 0”

Offerpad Solutions Inc. shareholders approved Advisory (non-binding) approval of compensation of named executive officers at the 2026-06-03 meeting.

“Proposal 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 10,610,068 638,376 5,261,776 11,118,728”

Offerpad Solutions Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-03 meeting.

“Proposal 2 - Ratification of the appointment of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,756,195 741,462 5,131,291 0”

Offerpad Solutions Inc. shareholders approved Election of two Class II directors for a term expiring at the 2029 annual meeting at the 2026-06-03 meeting.

“Proposal 1 - Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2029 and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Donna Corley 10,994,009 5,516,211 11,118,728 Tela Mathias 11,163,997 5,346,223 11,118,728”

LB PHARMACEUTICALS INC shareholders approved Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

LB PHARMACEUTICALS INC shareholders approved Election of Class I Directors to serve three-year terms until 2029 at the 2026-06-03 meeting.

“The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal.”

Verrica Pharmaceuticals Inc. shareholders approved Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. at the 2026-06-05 meeting.

“Proposal No. 4 : Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan 11,142,881 433,852 36,469 Broker Non-Votes: 2,456,129”

Verrica Pharmaceuticals Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-05 meeting.

“Proposal No. 3 : Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of KPMG LLP 14,058,234 8,055 3,042”

Verrica Pharmaceuticals Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. at the 2026-06-05 meeting.

“Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 11,564,256 34,355 14,591 Broker Non-Votes: 2,456,129.”

Verrica Pharmaceuticals Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-05 meeting.

“Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Paul B. Manning 11,543,142 70,060 Lawrence Eichenfield 11,523,540 89,662 Broker Non-Votes: 2,456,129. All nominees were elected.”

Palantir Technologies Inc. shareholders rejected Stockholder Proposal Entitled "Political Spending Disclosure" at the 2026-06-03 meeting.

“Proposal 6 – Stockholder Proposal Entitled “Political Spending Disclosure.” The stockholders did not approve the stockholder proposal entitled “Political Spending Disclosure.” After giving effect to the voting power of the common stock, the number of votes cast for and against, and the number of abstentions and broker non-votes with respect to, Proposal 6 are set forth below: For Against Abstained Broker Non-Votes 608,889,045 1,717,284,070 28,684,887 381,084,411”

Palantir Technologies Inc. shareholders rejected Stockholder Proposal Entitled "Human Rights Impact Assessment" at the 2026-06-03 meeting.

“Proposal 5 – Stockholder Proposal Entitled “Human Rights Impact Assessment.” The stockholders did not approve the stockholder proposal entitled “Human Rights Impact Assessment.” After giving effect to the voting power of the common stock, the number of votes cast for and against, and the number of abstentions and broker non-votes with respect to, Proposal 5 are set forth below: For Against Abstained Broker Non-Votes 290,935,808 2,042,181,192 21,741,002 381,084,411”

Palantir Technologies Inc. shareholders rejected Stockholder Proposal Entitled "Independent Report on Due Diligence Process" at the 2026-06-03 meeting.

“Proposal 4 – Stockholder Proposal Entitled “Independent Report on Due Diligence Process.” The stockholders did not approve the stockholder proposal entitled “Independent Report on Due Diligence Process.” After giving effect to the voting power of the common stock, the number of votes cast for and against, and the number of abstentions and broker non-votes with respect to, Proposal 4 are set forth below: For Against Abstained Broker Non-Votes 192,995,867 2,137,396,027 24,466,108 381,084,411”

Palantir Technologies Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-03 meeting.

“Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. After giving effect to the voting power of the common stock, the number of votes cast for and against, and the number of abstentions and broker non-votes with respect to, Proposal 3 are set forth below: For Against Abstained Broker Non-Votes 1,987,926,773 357,136,775 9,794,454 381,084,411”

Palantir Technologies Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-03 meeting.

“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. After giving effect to the voting power of the common stock, the number of votes cast for and against, and the number of abstentions and broker non-votes with respect to, Proposal 2 are set forth below: For Against Abstained Broker Non-Votes 3,098,257,509 15,840,752 2,928,548 0”

Palantir Technologies Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.

“Proposal 1 – Election of Directors. Each of the following nominees was elected to serve as a director and to hold office until the Company’s next annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal. After giving effect to the voting power of the common stock, the number of votes cast for and withheld, and the number of broker non-votes, with respect to each of the nominees are set forth below: Nominee For Withheld Broker Non-Votes Alexander Karp 3,221,448,690 237,998,436 381,084,411 Stephen Cohen 3,216,120,642 243,326,484 381,084,411 Peter Thiel 3,007,188,835 452,258,291 381,084,411 Alexander Moore 2,956,909,699 502,537,427 381,084,411 Alexandra Schiff 2,979,284,938 480,162,188 381,084,411 Lauren Friedman Stat 3,431,802,165 27,644,961 381,084,411 Eric Woersching 3,434,608,279 24,838,847 381,084,411”

26North BDC, Inc. shareholders approved Ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal 2 : By the vote shown below, the stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

26North BDC, Inc. shareholders approved Election of Wendell E. Pritchett as a Class III director at the 2026-06-04 meeting.

“Proposal 1 : By the votes shown below, the stockholders elected Wendell E. Pritchett as a Class III director.”

LIGAND PHARMACEUTICALS INC shareholders approved Approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan.

“Proposal 4. The approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan. In accordance with the results below, the proposal was approved.”

LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.

“Proposal 3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers. In accordance with the results below, the proposal was approved.”

LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

“Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. In accordance with the results below, the selection of Ernst & Young LLP was ratified.”

LIGAND PHARMACEUTICALS INC shareholders approved Election of eight members of the Board of Directors for terms expiring at the 2027 annual meeting.

“Proposal 1. The election of eight members of the Board of Directors of the Company for terms expiring at the 2027 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director of the Company.”

FirstCash Holdings, Inc. shareholders approved Approval of Reincorporation of the Company to the State of Texas by Conversion at the 2026-06-09 meeting.

“The stockholders approved the reincorporation of the Company to the State of Texas by conversion.”

FirstCash Holdings, Inc. shareholders approved Advisory Approval of the Compensation of the Company's Named Executive Officers at the 2026-06-09 meeting.

“The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”

FirstCash Holdings, Inc. shareholders approved Ratification of Selection of RSM LLP as Independent Registered Public Accounting Firm for Year Ended December 31, 2026 at the 2026-06-09 meeting.

“The stockholders ratified the selection of RSM LLP as independent registered public accounting firm of the Company for the year ended December 31, 2026.”

FirstCash Holdings, Inc. shareholders approved Election of Director Nominees for a Term of Three Years at the 2026-06-09 meeting.

“The stockholders elected the director nominees for a term of three years.”

Titan Machinery Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's Registered Independent Public Accounting Firm for the fiscal year ended January 31, 2027. at the 2026-06-08 meeting.

“Proposal No. 3 —The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's Registered Independent Public Accounting Firm for the fiscal year ended January 31, 2027. For Against Abstained Broker Non-Votes 21,553,008 12,950 2,032 -”

Titan Machinery Inc. shareholders approved Non-binding resolution approving the compensation of the Company’s Named Executive Officers. at the 2026-06-08 meeting.

“Proposal No. 2 — The stockholders adopted the non-binding resolution approving the compensation of the Company’s Named Executive Officers as described in the Company’s 2026 Proxy Statement. For Against Abstained Broker Non-Votes 19,510,725 944,273 8,253 1,104,739”

Titan Machinery Inc. shareholders approved Elect Class I Nominees to the Board of Directors for a three-year term. at the 2026-06-08 meeting.

“The Annual Meeting was held on June 8, 2026. The votes cast with respect to each item of business properly presented at the meeting are as follows: Proposal No. 1 — The stockholders elected the following Class I nominees to the Board of Directors for a three-year term. For Withheld Broker Non-Votes Tony Christianson 19,601,171 862,080 1,104,739 Christine Hamilton 17,045,392 3,417,859 1,104,739 Bryan Knutson 20,180,084 283,167 1,104,739”

Vera Bradley, Inc. shareholders approved Approval to add an additional 3,000,000 shares of common stock to the 2020 Equity and Incentive Plan at the 2026-06-04 meeting.

“approved an amendment to the 2020 Equity and Incentive Plan to add an additional 3,000,000 shares of common stock to the plan”

Vera Bradley, Inc. shareholders approved Advisory Approval of the Company's Named Executive Officer Compensation at the 2026-06-04 meeting.

“approved, on an advisory basis, the compensation of the Company’s named executive officers”

Vera Bradley, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“ratified the appointment of Deloitte & Touche LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending January 30, 2027”

Vera Bradley, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“elected Ian Bickley, Ivan Brockman, Kristina Cashman, Robert J. Hall, Andrew Meslow, and Jessica Rodriguez to serve as Directors of the Company’s Board of Directors for a one-year term”

CervoMed Inc. shareholders approved Amendment No. 1 to the 2025 Equity Incentive Plan at the 2026-06-08 meeting.

“To approve Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan.”

CervoMed Inc. shareholders approved Advisory approval of executive compensation for fiscal year 2024 at the 2026-06-08 meeting.

“To approve, on an advisory basis, the compensation of the Company’s named executive officers during the year ended December 31, 2024, as disclosed in the Proxy Statement.”

CervoMed Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for 2026 at the 2026-06-08 meeting.

“To ratify the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”

CervoMed Inc. shareholders approved Election of eight directors at the 2026-06-08 meeting.

“The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.”

OOMA INC shareholders approved Non-Binding Advisory Vote on the Compensation of Our Named Executive Officers at the 2026-06-04 meeting.

“Proposal No. 3: Non-Binding Advisory Vote on the Compensation of Our Named Executive Officers. The stockholders approved, on an advisory basis, the Company's executive compensation for the fiscal year ended January 31, 2026. The voting results were as follows: For Against Abstain Broker Non-votes 17,705,978 528,798 47,514 5,166,292”

OOMA INC shareholders approved Ratification of the Appointment of the Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“Proposal No. 2: Ratification of the Appointment of the Independent Registered Public Accounting Firm. The stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending January 31, 2027. There were no broker non-votes on this proposal. The results of the ratification were as follows: For Against Abstain 23,265,635 17,738 165,209”

OOMA INC shareholders approved Election of Directors at the 2026-06-04 meeting.

“Proposal No. 1: Election of Directors. The following individuals were elected to the Board as Class II directors to hold office until the 2029 annual meeting of stockholders or until such director's successor is duly elected and qualified or until his or her earlier resignation or removal. The results of the election were as follows: Nominee For Withheld Susan G. Butenhoff 12,259,460 6,022,830 Russ Mann 17,355,865 926,425 Broker Non-votes (all Directors) 5,166,292”

AN2 Therapeutics, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848”

AN2 Therapeutics, Inc. shareholders approved Election of the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors at the 2026-06-03 meeting.

“1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125”

BTCS Inc. shareholders approved To approve, if necessary, the adjournment of the Annual Meeting to a later date or time to permit further solicitation and vote of proxies if there were not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote at the 2026-06-08 meeting.

“To approve, if necessary, the adjournment of the Annual Meeting to a later date or time to permit further solicitation and vote of proxies if there were not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote. 23,765,250 7,692,466 — 494,459 0”

BTCS Inc. shareholders approved To approve an amendment to the 2021 Plan to add an evergreen provision that automatically increases the shares available for issuance under the 2021 Plan by 2.5% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, beginning with fiscal year 2027 at the 2026-06-08 meeting.

“To approve an amendment to the 2021 Plan to add an evergreen provision that automatically increases the shares available for issuance under the 2021 Plan by 2.5% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, beginning with fiscal year 2027. 12,196,037 6,421,729 — 63,966 13,270,443”

BTCS Inc. shareholders approved To approve an amendment to the 2021 Plan to permit shares tendered for payment of option exercises or withheld for tax obligations and shares related to stock-settled awards to again be available for future grants under the 2021 Plan at the 2026-06-08 meeting.

“To approve an amendment to the 2021 Plan to permit shares tendered for payment of option exercises or withheld for tax obligations and shares related to stock-settled awards to again be available for future grants under the 2021 Plan. 17,143,516 1,483,565 — 54,651 13,270,443”

BTCS Inc. shareholders approved To approve an amendment to increase the number of shares of common stock authorized for issuance under the BTCS Inc. 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to 24,500,000 shares at the 2026-06-08 meeting.

“To approve an amendment to increase the number of shares of common stock authorized for issuance under the BTCS Inc. 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to 24,500,000 shares. 12,471,715 6,162,939 — 47,078 13,270,443”